TAWAM HOSPITAL
🇦🇪United Arab Emirates
- Country
- 🇦🇪United Arab Emirates
- Ownership
- -
- Employees
- -
- Market Cap
- -
Ellipses Pharma Launches First Phase 1/2 Oncology Trial in the UAE with RET Inhibitor EP0031/A400
• Ellipses Pharma has initiated a Phase 1/2 clinical trial in the UAE, marking a significant advancement in the region's oncology research landscape.
• The trial will evaluate EP0031/A400, a next-generation selective RET inhibitor, for treating RET-altered tumors, particularly in non-small cell lung cancer and thyroid cancer.
• EP0031/A400 has received Orphan Drug and Fast Track designations from the FDA, expediting its development for serious conditions with unmet medical needs.
© Copyright 2025. All Rights Reserved by MedPath